Last updated: June 3, 2026
DIANEAL PD-1 W/ Dextrose 2.5% in Plastic Container: Supplier Map, Manufacturing Footprint, and Supply-Limit Risks
Executive summary: DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER is supplied in the U.S. by Baxter Healthcare Corporation and distributed through Baxter’s commercial network. The product’s active components are produced as pharmaceutical chemicals and then assembled into the final peritoneal dialysis (PD) solution in plastic containers by Baxter’s manufacturing sites. For procurement and continuity planning, supplier risk is dominated by (1) container and solution-filling capacity for sterile PD fluids, (2) upstream sourcing for dextrose and buffer systems (lactate-based formulations in this category), and (3) regulatory batch release throughput at Baxter-manufacturing locations.
Who supplies DIANEAL PD-1 W/ Dextrose 2.5% in plastic container in the US?
Answer: Baxter Healthcare Corporation is the U.S. supplier of DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER.
What is the company role (manufacturer vs. distributor vs. labeler)?
- Labeler/sponsor for U.S. commercial supply: Baxter Healthcare Corporation.
- Primary commercial sourcing: Baxter’s manufacturing of sterile PD solutions in plastic containers, followed by U.S. distribution through Baxter channels.
What manufacturing sites make DIANEAL PD-1 2.5% dextrose in plastic containers?
Answer: The final assembly and sterile filling of DIANEAL PD-1 PD solutions into plastic containers is done by Baxter at its PD-fluid manufacturing network. Site-specific details for this specific SKU are typically determined by FDA listing entries under the product’s manufacturing/labeler records.
Why PD solution manufacturing is a capacity bottleneck
Peritoneal dialysis solutions are sterile, multi-component products that require:
- controlled sterile solution preparation for dextrose and buffer components,
- container sterilization and validated filling,
- batch-level release for pH, osmolality, sterility, and container integrity.
This structure makes supply continuity dependent on Baxter’s validated filling lines and sterile release timelines.
What are the upstream chemical suppliers for DIANEAL PD-1 (dextrose and buffers)?
Answer: Upstream sourcing for DIANEAL PD-1’s inputs (notably dextrose and buffering components) is drawn from pharmaceutical-grade chemical supply chains used by Baxter across PD and IV fluid portfolios. Exact named suppliers are not consistently published for the specific finished good SKU in public labeler-level datasets.
What inputs dominate upstream sourcing
For the PD-1 dextrose 2.5% category, the upstream supply chain typically depends on:
- pharmaceutical-grade dextrose monohydrate or dextrose solutions,
- buffer system components used in PD fluids (commonly lactate-based buffers for the PD fluid family),
- electrolyte-grade salts used in the osmotic and ionic composition,
- sterile-grade water systems for formulation,
- plastic container materials compatible with PD fluids.
What container and packaging suppliers affect DIANEAL PD-1 availability?
Answer: Container supplier identity is generally controlled through Baxter’s qualified packaging and container-manufacturing vendor network for sterile plastic PD containers. The container format drives procurement risk because PD solutions are validated for specific container materials and closure systems.
Where container constraints show up in supply
- container-film supply and molding capacity,
- closure and port component availability (if applicable),
- sterile barrier integrity validation requalification cycles,
- line changeover time and container SKU-specific packaging operations.
Is DIANEAL PD-1 2.5% dextrose the same product across all regions, and do suppliers differ by geography?
Answer: Finished-good manufacturer and labeler generally align to Baxter’s network in the U.S., but global availability can be sourced from different Baxter regional manufacturing sites depending on distribution requirements and regulatory approvals.
How geography changes the “supplier” definition
For procurement, supplier mapping must separate:
- commercial supplier (who ships into the market),
- manufacturing site (who makes the finished sterile fluid),
- regulatory-listed manufacturer (who is on the product’s FDA listing).
What FDA listings identify the supplier and manufacturing chain for DIANEAL PD-1?
Answer: FDA product listing records for DIANEAL products identify the U.S. labeler and the manufacturing site(s) responsible for the finished dosage form and packaging.
Orange Book status
- DIANEAL PD-1 is not positioned as a typical small-molecule “listed drug” with Orange Book exclusivity in the way many oral drugs are. The key regulatory status for PD solutions is usually tracked via FDA labeling and product listing rather than an Orange Book patent or exclusivity framework.
What supply risks exist for DIANEAL PD-1, and how do they map to supplier dependencies?
Answer: Supply risk is concentrated in sterile PD-fluid production constraints and bottlenecks in container packaging and batch release capacity.
Risk drivers
- sterile filling line capacity for plastic-container PD solutions,
- upstream chemical and buffer supply lead times,
- container-film and port component availability,
- batch-release throughput at manufacturing sites,
- regulatory holds tied to deviations, sterility results, or container integrity.
Which competitors supply PD-1 style dextrose PD solutions (and do they share the same supplier ecosystem)?
Answer: The DIANEAL PD-1 2.5% dextrose line sits in Baxter’s peritoneal dialysis solutions portfolio. Competitors include other PD solution manufacturers that may supply cycler and continuous ambulatory PD solutions in comparable strength ranges, but their supplier ecosystems differ because container and manufacturing lines are typically product- and site-specific.
Procurement implication
Even when strengths match (2.5% dextrose), substitution requires matching:
- container type and fill volume,
- buffer system,
- electrolyte composition,
- sterility and regulatory labeling.
How should procurement teams verify “supplier” for DIANEAL PD-1 shipments (lot-by-lot)?
Answer: Procurement should verify supplier and manufacturing chain at the lot level using:
- product labeling on the box and unit level,
- U.S. FDA listing data associated with the specific NDC,
- CoA and lot release documentation provided by Baxter distribution channels.
What to capture in supplier verification
- manufacturer name and facility on CoA,
- labeling NDC and lot number,
- container configuration and packaging version,
- expiration and storage conditions.
Key tables: supplier mapping by procurement definition
Table 1: DIANEAL PD-1 supplier roles (U.S.)
| Procurement definition |
Who supplies |
What to validate |
| Commercial supplier (ships in market) |
Baxter Healthcare Corporation |
shipment documents, lot packaging label |
| Finished dosage form manufacturer |
Baxter manufacturing network (site identified via FDA product listing and lot CoA) |
facility on CoA, batch number |
| Upstream chemical suppliers |
Baxter-qualified pharmaceutical chemical suppliers |
supplier qualification files (internal), CoA origin |
| Container/packaging suppliers |
Baxter-qualified container and closure vendors |
container material compatibility and CoA/packaging traceability |
Key Takeaways
- Baxter Healthcare Corporation is the U.S. commercial supplier for DIANEAL PD-1 W/ Dextrose 2.5% in plastic container.
- The decisive supply dependencies are sterile PD-fluid filling capacity and qualified plastic container/closure availability, not interchangeable chemical inputs.
- For continuity planning, procurement should verify lot-level manufacturer and facility using CoA and FDA listing mapping for the specific NDC.
FAQs
-
Who is the labeler for DIANEAL PD-1 with dextrose 2.5% in plastic containers in the United States?
Baxter Healthcare Corporation.
-
Is DIANEAL PD-1 2.5% dextrose in a plastic container available through wholesalers other than Baxter?
DIANEAL is distributed through Baxter’s commercial distribution channels; reseller presence depends on contract distribution arrangements by region and accounts.
-
Does the manufacturer of DIANEAL PD-1 change based on shipment lot?
Lot-level facilities can differ if Baxter uses multiple qualified manufacturing sites; confirm via CoA and the lot labeling.
-
Do PD solution container suppliers affect DIANEAL availability?
Yes. Container materials and closure components are validated for the finished product and can constrain supply if packaging capacity or components are delayed.
-
Are there FDA Orange Book patents driving DIANEAL PD-1 substitution?
PD solution products are typically not evaluated on an Orange Book patent framework in the same manner as many small-molecule drugs; regulatory control is managed through product labeling and FDA listing status.
References (APA)
- FDA. (n.d.). Drug Product Database: DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (labeler/manufacturer listing records). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. (n.d.). Drug Listing Data. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
